Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Partmann who wrote (3065)	8/14/2002 3:18:19 PM
From: biostruggle	Read Replies (1) of 10345

Skelaxin June 2002 Elan got approval of bioequilance study in fasting condition. FDA has labeled Skelaxin a drug with difficult pharmokinetics. As a result of the new lableing a generic would have to do a patient study under fasting conditions to demonstrate bio-equivelance. I believe skelaxin is free from generic competition for at least another year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next